Vivos' Vida Appliance Shows 100% Insomnia Improvement, Targets Multi-Billion Market
VVOS sits 60% above its 52-week low of $0.383 on light trading volume (0.1× avg).
Summary
Vivos Therapeutics announced compelling clinical data for its Vida® oral appliance, showing statistically significant improvement in insomnia severity in 100% of 37 study participants, with an average 65% reduction in Insomnia Severity Index scores. This news arrives as the company faces significant financial distress, including a 'going concern' warning and Nasdaq delisting risk, as detailed in recent 10-K and 10-Q filings and debt restructuring announcements. The company believes this data supports expansion into a multi-billion-dollar global insomnia market, potentially offering a critical new revenue stream. Future multi-center studies and provider adoption will be crucial to realizing this substantial market opportunity.
At the time of this announcement, VVOS was trading at $0.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.9M. The 52-week trading range was $0.38 to $7.95. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.